<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04063852</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00153287</org_study_id>
    <nct_id>NCT04063852</nct_id>
  </id_info>
  <brief_title>PTNS on Urinary and Global Quality of Life in MS Patients</brief_title>
  <acronym>PTNSinMS</acronym>
  <official_title>Impact of Percutaneous Posterior Tibial Nerve Stimulation on Urinary and Global Quality of Life in Multiple Sclerosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centered, prospective, longitudinal, observational cohort study of patients&#xD;
      with MS who suffer from lower urinary tract symptoms (LUTS) and are refractory to two prior&#xD;
      treatment modalities who have elected to pursue PTNS therapy for LUTS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 27, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Frequency and/or Urinary Incontinence Episodes on 3 day voiding diary</measure>
    <time_frame>up to 24 months.</time_frame>
    <description>Change from baseline in the median number of urinary frequency and/or urinary incontinence episodes on a 3 day voiding diary at 3, 12, and 24 months</description>
  </primary_outcome>
  <other_outcome>
    <measure>American Urological Association (AUA) Symptom Score</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Change from baseline of the total AUA Symptom Score at 3, 12, and 24 months&#xD;
7 question scale. Score Ranges 0-35. Higher scores indicate worse lower urinary tract symptoms.&#xD;
AUA Bother Subscore: Single question item that is part of the AUA symptom score, but not calculated for the overall score. range is 0-6 with 6 indicating terrible bother from urinary symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Michigan Incontinence Symptom Index</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Change from baseline of the total Michigan Incontinence Symptom Index at 3, 12, and 24 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurogenic Bladder Symptom Score</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Change from baseline of the total Neurogenic Bladder Symptom Score at 3, 12, and 24 months&#xD;
The NBSS consists of 24 questions. The first question classifies patients by bladder management, but does not make up part of the numeric score. The remaining questions address 3 domains: incontinence, storage and voiding, and consequences. The final question is an overall quality of life question. The total score can range from 0 (no symptoms at all) to 74 (maximum symptoms). The median time to complete the NBSS is 6 minutes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Status Questionnaire (SF-12),</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Change in from baseline of the total Health Status Questionnaire (SF-12) at 3, 12, and 24 months&#xD;
12 item scale with ranges from 0-100. where a zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sexual Satisfaction Scale (SSS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Change from baseline of the total Sexual Satisfaction Scale (SSS) at 3, 12, and 24 months&#xD;
Raw scores on the 4 sexual satisfaction items (Items 2-5) are summed to create a total score. Thus, this scale can range from 4-24. Higher scores indicate greater problems with sexual satisfaction.</description>
  </other_outcome>
  <other_outcome>
    <measure>Bowel Control Scale (BCS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Change from baseline of the total Bowel Control Scale (BCS) at 3, 12, and 24 months&#xD;
Raw scores on the 5 items are summed to create a Bowel Control Scale (BWCS) total score. Scores can range from 0-26, with higher scores indicating greater bowel control problems.</description>
  </other_outcome>
  <enrollment type="Actual">23</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <condition>Neurogenic Bladder</condition>
  <condition>Overactive Bladder</condition>
  <condition>Urinary Incontinence</condition>
  <condition>Urinary Urge Incontinence</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting to the urology clinic at a tertiary care referral center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Multiple Sclerosis&#xD;
&#xD;
          -  Lower urinary tract symptoms (urinary frequency, urgency and/or incontinence)&#xD;
&#xD;
          -  Failed prior first and second line therapy (behavioral and pharmacotherapy)&#xD;
&#xD;
          -  Electing for Posterior Tibial Nerve Stimulation therapy for urinary symptoms&#xD;
&#xD;
          -  Patients performing Intermittent Catheterization are Eligible&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Indwelling catheters (urethral or suprapubic)&#xD;
&#xD;
          -  Currently pregnant or planning pregnancy&#xD;
&#xD;
          -  Unable to attend weekly office visits for PTNS&#xD;
&#xD;
          -  Urodynamic findings of bladder outlet obstruction&#xD;
&#xD;
        History of:&#xD;
&#xD;
        bladder reconstruction (augmentation cystoplasty, catheterizable channel) cystectomy&#xD;
        bladder stones pacemaker or defibrillator malignancy of bladder sacral neuromodulation&#xD;
        intravesical injection of onabotulinum toxin within 9 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>John Stoffel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giulia Lane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Giulia Lane</investigator_full_name>
    <investigator_title>Urology Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

